|
|
||||||||
From the Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin, Ireland.
PURPOSE. To design, generate, and compare in vitro a range of hammerhead ribozymes targeting retinal transcripts implicated in autosomal dominant retinitis pigmentosa (adRP) and thereby identify ribozymes that may be valuable as therapeutic agents for adRP. To address mutational heterogeneity in rhodopsin and peripherin-linked adRP using mutation-independent ribozyme-based therapeutic approaches.
METHODS. Ribozyme and cDNAs constructs were cloned into pcDNA3 and expressed in vitro from the T7 promoter. Cleavage reactions were separated on polyacrylamide gels, visualized by autoradiography, and quantified using an instant imager. Ribozymes targeting rhodopsin and peripherin transcripts in a mutation-independent manner (Rz9, Rz10, and Rz40) and a multimeric ribozyme (RzMM) targeting rhodopsin transcripts were evaluated for in vitro activity. Parameters such as Vmax, Km, k2 and k-1 were established for each ribozyme.
RESULTS. Four ribozymes targeting retinal transcripts were evaluated. Mutation-independent ribozymes targeting degenerate sites or untranslated regions in retinal transcripts resulted in cleavage products of predicted size, whereas transcripts from modified replacement genes remained intact. Detailed kinetic evaluation of ribozymes revealed substantial differences in cleavage rates between ribozymes.
CONCLUSIONS. Mutation-independent hammerhead ribozymes targeting rhodopsin and peripherin have been screened in vitro, and a number of extremely efficient ribozymes identified subsequent to detailed kinetic analyses, suggesting that these ribozymes may provide mutation-independent methods of treating adRP. These are the first ribozymes reported that potentially will provide benefit for inherited retinopathies.
This article has been cited by other articles:
![]() |
A. Aherne, A. Kennan, P. F. Kenna, N. McNally, D. G. Lloyd, I. L. Alberts, A.-S. Kiang, M. M. Humphries, C. Ayuso, P. C. Engel, et al. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa Hum. Mol. Genet., March 15, 2004; 13(6): 641 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.A. Wood, B. Trulzsch, A. Abdelgany, and D. Beeson Therapeutic gene silencing in the nervous system Hum. Mol. Genet., October 15, 2003; 12(90002): R279 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Millington-Ward, C. Allers, G. Tuohy, P. Conget, D. Allen, H. P. McMahon, P. F. Kenna, P. Humphries, and G. J. Farrar Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta Hum. Mol. Genet., September 15, 2002; 11(19): 2201 - 2206. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. McNally, P. F. Kenna, D. Rancourt, T. Ahmed, A. Stitt, W. H. Colledge, D. G. Lloyd, A. Palfi, B. O'Neill, M. M. Humphries, et al. Murine model of autosomal dominant retinitis pigmentosa generated by targeted deletion at codon 307 of the rds-peripherin gene Hum. Mol. Genet., May 1, 2002; 11(9): 1005 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Caplen, J. P. Taylor, V. S. Statham, F. Tanaka, A. Fire, and R. A. Morgan Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference Hum. Mol. Genet., January 1, 2002; 11(2): 175 - 184. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |